Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Allowed: BRAF driver mutation

Must have received: anti-PD-1 therapy

Has progressed on a prior PD-1/PD-L1 treatment

Cannot have received: BRAF inhibitor

Exception: allowed if patient declines or is unable to tolerate BRAF and/or MEK inhibitors

Presence of B-RAF driver mutation without prior receipt of BRAF +/- MEK inhibitors, unless patient declines BRAF +/-MEK inhibition for any reason or is unable to tolerate BRAF and/or MEK inhibitors.

Cannot have received: allogeneic tissue/solid organ transplant

Participants with a history of allogeneic tissue/solid organ transplant

Cannot have received: any prior investigational or standard cancer therapy (except PD-1/PD-L1, chemotherapy or radiation within 6-9 weeks of first dose)

Exception: PD-1/PD-L1, chemotherapy, or radiation allowed if outside 6-9 week window

Any prior investigational or standard cancer therapy, with exception of PD-1/PD-L1 (includes nivolumab + Relatlimab) therapy, chemotherapy or radiation within 6-9 weeks of the first dose of the investigational therapy